Basic therapy for rheumatoid arthritis: Nonsteroidal anti-inflammatory drugs

Comprehensive Therapy

Volumn 25, Issue 8-10, 1999, Pages 427-433

  Daoud, Katja F ^a   Jackson, Christopher G ^a   Williams, H James ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; IBUPROFEN; INDOMETACIN; KETOROLAC TROMETAMOL; MECLOFENAMATE SODIUM; NABUMETONE; NAPROXEN; NEW DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; SULINDAC;

ANAPHYLAXIS; ARTICLE; ASEPTIC MENINGITIS; BLOOD TOXICITY; DRUG EFFICACY; DRUG SELECTIVITY; ENZYME INHIBITION; ERYTHEMA MULTIFORME; GASTROINTESTINAL SYMPTOM; HUMAN; NEPHROTOXICITY; PROSTAGLANDIN SYNTHESIS INHIBITION; RHEUMATOID ARTHRITIS; TOXIC EPIDERMAL NECROLYSIS;

EID: 0032879627     PISSN: 00988243     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02944294     Document Type: Article

References (27)

1. McDuffie FC. Morbidity impact of rheumatoid arthritis on society. Am J Med. 1985;78(suppl 1A):1-5.
2. Markenson JA. Worldwide trends in the socioeconomic impact and long-term prognosis of rheumatoid arthritis. Semin Arthritis Rheum. 1991;21(suppl 1):4-12.
3. Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum. 1990; 33:305-315.
4. Fremont-Smith K, Bayles TB. Salicylate therapy in rheumatoid arthritis. JAMA. 1965;192:1133-1136.
5. Heller CA, Ingelfinger JA, Goldman P. Nonsteroidal antiinflammatory drugs and aspirin: Analyzing the scores. Pharmacotherapy. 1985;5:30-38.
6. Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs: differences and similarities. N Engl J Med. 1991;324:1716-1725.
7. Dewitt DL. Prostaglandin endoperoxide synthase: regulation of enzyme expression. Biochim Biophys Acta. 1991;1083:121-134.
8. Vane JR, Botting RM. Mechanism of action of anti-inflammatory drugs. Scand J Rheumatol. 1996;25(suppl 102):9-21.
9. Crofford LJ, Wilder RL, Ristimaki AP, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. J Clin Invest. 1994;93:1095-1101.
10. Tomlinson A, Appleton I, Moore AR, et al. Cyclo-oxygenase and nitric oxide synthase isoforms in rat carrageenin-induced pleurisy. Br J Pharmacol 1994;113:693-98.
11. Nogawa, S, Zhang R, Ross ME, Iadecola C. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci. 1997;17:2746-2755.
12. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest. 1994;94:2504-2510.
13. Dinchuk JE, Car BD, Focht RJ, et al. Renal abnormalities and altered inflammatory response in mice lacking cyclooxygenase II. Nature. 1995;378:406-407.
14. Slater DM, Bryer LC, Newton R, Moore GE, Bennett PR. Expression of cyclooxygenase type 1 and type 2 in human fetal membranes at term. Am J Obstet Gynecol. 1995;172(1): 77-82.
15. Eberhart CE, Coffey RJ, Radhika A, et al. Upregulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107: 1183-1188.
16. Williams HJ, Ward JR, Marlene JE, et al. Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum. 1993;36: 1196-1206.
17. Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Am J Gastroenterol. 1998;93:2037-2046.
18. Polisson R. Nonsteroidal anti-inflammatory drugs: Practical and theoretical considerations in their selection. Am J Med. 1996;100(suppl2A)31s-36s.
19. Clive DM, Stoff SS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1984;310: 563-572.
20. Spangler RS. Cyclooxygenase 1 and 2 in rheumatic disease: implications for nonsteroidal anti-inflammatory drug therapy. Semin Arthritis Rheum. 1996;26:435-446.
21. Vane J. Differential inhibition of cyclooxygenase isoforms: an explanation of the actions of NSAIDs. J Clin Rheumatol. 1998;4(5):s3-s10.
22. Mitchell JA, Adarasereenont P, Themermann C, et al. Selectivity of nonsteroidal antiinflammtory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA. 1994;90:11693-11697.
23. Meade EA, Smith WL, Dewitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1993;268:3310-3314.
24. Distal M, Mueller C, Bluhmki E, Fries J. Safety of meloxican: a global analysis of clinical trials. Br J Rheumatol. 1996; 35(suppl 1):68-77.
25. Barner A. Review of clinical trials and benefit/risk ratio of meloxicam. Scand J Rheumatol 1996;102(suppl):29-37.
26. Furst DE. Meloxicam: selective COX-2 inhibition in clinical practice. Semin Arthritis Rheum. 1997;26(suppl 1):21-27.
27. Freed MI, Audet PA, Zariffa N, et al. Comparative effects of nabumetone, sulindac, and indomethacin on urinary prostaglandin excretion and platelet function in volunteers. J Clin Pharmacol 1994;34:1098-1108.